ArticlePDF Available

MORTALITY OF ACUTE MYOCARDIAL INFARCTION IN RELATION WITH TIMI RISK SCORE

Authors:
  • HEART AND GENERAL HOSPITAL JAIPUR

Abstract and Figures

Background: The Thrombolysis in Myocardial Infarction (TIMI) risk score is said to be an important factor in predicting mortality risk in fibrinolysis-eligible STEMI patients. An attempt was made to assess the situation by comparing risk stratification based on the TIMI score with the hospital outcome of such individuals. Methods: 145 STEMI patients were included in this srudy , TIMI risk scores were calculated and analysed vis-Ã -vis various relevant parameters.. Based on their TIMI scores, the patients were placed into three risk groups: low-risk,moderate-risk, and high-risk. All patients received standard anti-ischemic medication, were thrombolyzed, monitored in the ICCU, and monitored throughout their hospital stay for post-MI sequelae. Results: According to the TIMI risk score, 79 patients (54.5%) had low-risk , 48 (33.1%) to the moderate-risk , and 18 (12.4%) to the high-risk . The highest mortality rate (total 17 deaths) was found in the high-risk group (55.6%), followed by moderate-risk (12.2%) and low-risk (1.28%) groups, respectively. Killips categorization grade 2-4 had the highest relative risk (RR-15.85) of the seven potentially dubious variables evaluated, followed by systolic BP 100mmHg (RR-10.48), diabetes mellitus (RR-2.79), and age >65 years (RR- 2.59). Conclusions: In patients with STEMI, the TIMI risk scoring system appears to be a straightforward, valid, and practical bedside tool for quantitative risk classification and short-term prognosis prediction.
Content may be subject to copyright.
ISSN: 2320-5407 Int. J. Adv. Res. 9(12), 403-407
403
Journal Homepage: - www.journalijar.com
Article DOI: 10.21474/IJAR01/13923
DOI URL: http://dx.doi.org/10.21474/IJAR01/13923
RESEARCH ARTICLE
MORTALITY OF ACUTE MYOCARDIAL INFARCTION IN RELATION WITH TIMI RISK SCORE
Owais Ahmed Wani1, Nasir Ali2, Ouber Qayoom1 and Rajveer Beniwal1
1. Dr NB Cardiology, SSH, GMC Jammu.
2. Consultant Cardiology, SSH, GMC Jammu.
……………………………………………………………………………………………………....
Manuscript Info Abstract
……………………. ………………………………………………………………
Manuscript History
Received: 10 October 2021
Final Accepted: 14 November 2021
Published: December 2021
Key words:-
AMI, In-Hospital Outcome, Myocardial
Infarction, TIMI Score, STEMI
Background: The Thrombolysis in Myocardial Infarction (TIMI) risk
score is said to be an important factor in predicting mortality risk in
fibrinolysis-eligible STEMI patients. An attempt was made to assess
the situation by comparing risk stratification based on the TIMI score
with the hospital outcome of such individuals.
Methods: 145 STEMI patients were included in this srudy , TIMI risk
scores were calculated and analysed vis-à-vis various relevant
parameters.. Based on their TIMI scores, the patients were placed into
three risk groups: 'low-risk,"moderate-risk,' and 'high-risk.' All patients
received standard anti-ischemic medication, were thrombolyzed,
monitored in the ICCU, and monitored throughout their hospital stay
for post-MI sequelae.
Results: According to the TIMI risk score, 79 patients (54.5%) had
low-risk , 48 (33.1%) to the moderate-risk , and 18 (12.4%) to the high-
risk . The highest mortality rate (total 17 deaths) was found in the high-
risk group (55.6%), followed by moderate-risk (12.2%) and low-risk
(1.28%) groups, respectively. Killips categorization grade 2-4 had the
highest relative risk (RR-15.85) of the seven potentially dubious
variables evaluated, followed by systolic BP 100mmHg (RR-10.48),
diabetes mellitus (RR-2.79), and age >65 years (RR- 2.59).
Conclusions: In patients with STEMI, the TIMI risk scoring system
appears to be a straightforward, valid, and practical bedside tool for
quantitative risk classification and short-term prognosis prediction.
Copy Right, IJAR, 2021,. All rights reserved.
……………………………………………………………………………………………………....
Introduction:-
Ischemic Heart Disease (IHD) is still the biggest cause of death worldwide, and the epidemic is on the rise. IHD and
stroke combined killed 12.5 million people in 2010, accounting for 1 in every 4 deaths worldwide, compared to 1 in
every 5 deaths in 1990; IHD ranked first in terms of Years of Life Lost (YLL) in 2010, compared to fourth in 1990.1
Worse, Indians are affected by cardiovascular diseases (CVD) a decade earlier than their western counterparts, with
IHD accounting for the majority of CVD death in India (83 percent ). 2-4
Inspite of therapeutic advances in MI management, large scale randomised clinical trials reported 6-9% early
mortality rates (30-35 days), even for patients receiving thrombolytic therapy within 6 hours of symptom onset.5,6
Careful attention to pivotal factors that increase the risk of early mortality may further elaborate the role of early
invasive therapeutics that would lower the fatality rate of ST Elevation Myocardial Infarction (STEMI). Effective
Corresponding Author:- Owais Ahmed Wani
Address:- Dr NB Cardiology, SSH , GMC Jammu.
ISSN: 2320-5407 Int. J. Adv. Res. 9(12), 403-407
404
risk stratification is integral to management of acute coronary syndromes. The Thrombolysis in Myocardial
Infarction (TIMI) risk score for STEMI is one such simple integral score purported to be a robust clinical tool for
mortality risk prediction in fibrinolysis-eligiblepatients with STEMI.7 It’s validation in local population is, however,
largely untested.
The purpose of this study was to determine the predictive importance of the TIMI risk score in a local community of
acute STEMI patients who were eligible for thrombolytic therapy, by connecting risk stratification by TIMI score
with hospital outcomes of these patients.
Methods:-
The current study was a prospective observational study that lasted two years, from september 2019 to
september 2021. It was conducted at a tertiary care government hospital in north India. All adult patients over the
age of 18 who presented to the Cardiology OPD or emergency department and with cardiac condition compelling
admission to ICCU; while satisfying the following inclusion criteria were enrolled.
Inclusion criteria
1. Patients with ST Elevation Myocardial Infarction (STEMI) presenting for the first time.
2. Patients with ST Elevation Myocardial Infarction (STEMI) eligible for thrombolysis. (As per the ACC/AHA
STEMI Management Guideline).8
Exclusion criteria
1. Patients with Non- ST Elevation Myocardial Infarction.
2. Patients with ST Elevation Myocardial Infarction (STEMI) in which thrombolysis is contraindicated due to any
reason.
3. Unwilling for consent.
An informed written consent was elicited from each participant before enrollment. All patients were thoroughly
evaluated; with detailed history, clinical examination, clinically indicated laboratory investigations and ECG. The
diagnosis of STEMI was considered if the patient fulfilled following 2 criteria-
1. Presence of chest pain or other symptoms suggestive of acute MI.
2. ST elevation on admission or during hospital evaluation in two or more contiguous leads (greater than 0.2mv in
lead V1, V2 and V3 or greater than 0.1mv in other leads).
The patients were divided into three risk groups, namely ‘low-risk’, ‘moderate-risk’ and ‘high-risk’ based on their
TIMI scores (0-4 low risk, 5-8 moderate risk, 9-14 high risk). All patients received routine anti-ischemic therapy and
were thrombolysed subsequently with 1.5 million IU of Streptokinase in 100 ml of normal saline over 60 minutes
followed by routine post MI management. The patients were closely monitored in ICCU and followed during their
hospital stay for occurrence of post-MI complications including death. Ethical approval was obtained from
Institutional Ethics Committee before proceeding with the study.
Statistical analysis was performed using chi-square test for comparing variables between three TIMI score groups.
Relative risks (RR) were calculated wherever suitable. P-value <0.05 was considered statistically significant.
STATA version 10.0 was used to perform statistical analysis.
Results:-
In total, 145 ST-Elevation Myocardial Infarction (STEMI) cases met the inclusion criteria, and TIMI scores were
generated for further categorization and analysis..
The participants' average age was 57.9+11.2 years, with females (63.3+7.5 years, n=34) having a higher age than
males (56.0+11.8 years, n=111). The most prevalent symptom reported by all patients was chest discomfort (136,
93.8 percent), which was followed by perspiration (63, 43.4 percent), vomiting (34, 23.4 percent), dyspnea (32, 22.1
percent), and palpitation (32, 22.1 percent) (17, 11.7 percent ). The median elapsed time before a patient could reach
a medical facility was 10.4+11.3 hours, with 106 (73.1%) individuals having an elapsed time of more than 4 hours
and 39 (26.7%) being seen within 4 hours. Out of 145 patients, 79 (54.5%) belonged to low-risk group, 48 (33.1%)
to moderate-risk group and 18 (12.4%) to high-risk group according to TIMI risk score. The mortality (total 17
ISSN: 2320-5407 Int. J. Adv. Res. 9(12), 403-407
405
deaths) was observed to be highest in the high-risk group (55.6%), followed by moderate-risk (12.2%) and low-risk
group (1.28%) respectively (Table 1).
Table 1:- Distribution of patients according to TIMI risk Scores.
TIMI RISK GROUP
PATIENTS
MORTALITY AMOUNG GROUP
NUMBER
%
NUMBER
%
LOW RISK
79
54.50%
1
1.30%
MODERATE RISK
48
33.1
6
12.20%
HIGH RISK
18
12.4
10
55.60%
The most prevalent risk factor was hypertension (79, 54.5 percent), followed by smoking (61, 42.1%), dyslipidemia
(39, 26.9%), diabetes mellitus (36, 24.8%), and having a family history of AMI (36, 24.8%). (34, 23.4 percent ). The
subsequent mortality and TIMI risk score grouping revealed significant associations for all the mentioned risk
factors (Table 2).
Anterior wall MI was shown to be more prevalent than other types of MI (92, 63.4 percent) (inferior wall MI- 26.2
percent , mixed MI- 10.4 percent ). Anterior wall MI was also more deadly, with 13 (14.1%) patients dying as a
result of the incident. P-value was significant for trend of TIMI risk scores across thevarious types of MIs. Forty-
four cases (30.3%) belonged to Killips classification grade 2-4, with significant association with TIMI risk score. As
many as 16 out of 44 (36.4%) belonging to Killips classification grade 2-4 expired.
Table 2:- TIMI Risk score groups and association of various risk factors.
Risk Factor
TIMI Risk score
Mortality
Low
Moderate
P Value
Hypertension (n=79)
12 (11.4%)
36 (45.6%)
28 (35.4%)
0.015
Smoking (n=61)
10 (16.4%)
33 (54.1%)
16 (26.2%)
0.026
Dyslipidemia (n=39)
10 (25.6%)
16 (41.0%)
14 (35.9%)
0.015
Diabetes Mellitus (n=36)
8 (22.2%)
24 (66.6%)
6 (16.7%)
0.011
AMI family history (n=34)
9 (26.5%)
13 (38.2%)
12 (35.3%)
0.037
Potentially suspect variables were checked for association with mortality amongst study participants. Out of the 7
variables studied, Killips classification grade 2-4 had the highest relative risk (RR-15.85) which was significant.
Other variables with significant relative risks signifying association with morality were systolic BP <100mmHg
(RR- 10.48), diabetes mellitus (RR- 2.79) and age >65 years (RR- 2.59) (Table 3).
Table 3:- Variables associated with in-hospital mortality amongst participants.
Variable
RR
95% CI
P- Value
Killips Grade 2-4
15.85
1.86-26.31
<0.001
Systolic BP <100 mmHg
10.48
4.03-27.27
<0.001
Diabetes mellitus
2.79
1.16-6.68
0.019
Age >65 years
2.59
1.08-6.23
0.030
Heart rate >110/min
2.14
0.86-5.30
0.092
Elapsed time >4 hours
1.71
0.52-5.65
0.36
Hypertension
1.34
0.95-1.91
0.16
Table 4:- Association of variables with TIMI risk scores.
Variable
Low risk (%)
Moderate risk (%)
High risk (%)
Systolic BP <100mmHg
4 (5.12)
11 (22.44)
12 (66.67%)
HR >100/min
34 (43.58)
26 (53.06)
8 (44.44)
Elapsed time > 4 hours
51 (65.38)
40 (81.63)
15 (85.33)
Weight <67 kg
73 (93.58)
48 (97.95)
18 (100)
Extensive ant. wall MI
44 (56.41)
35 (71.42)
15 (88.23)
Hospitalisation time <24
72 (92.8)
41 (83.67)
12 (70.58)
ISSN: 2320-5407 Int. J. Adv. Res. 9(12), 403-407
406
hrs
Elevated blood pressure
36 (46.15)
28 (57.14)
15 (88.23)
Angina
12 (15.38)
12 (24.48)
02 (11.76)
Diabetes mellitus
24 (30.76)
05 (10.2)
05 (29.41)
Selected variables were further studied to check for association with TIMI risk scores. Frequency of all the studied
variables was observed to be more in high risk group as compared to moderate and low risk groups; except in angina
and diabetes mellitus, where the frequency didn’t vary much (Table 4).
Discussion:-
In every acute coronary episode, early recognition is critical. Over the years, a variety of risk scores have been
offered. The Thrombolysis in Myocardial Infarction (TIMI) risk score, obtained from clinical trial populations, and
the Global Registry of Acute Coronary Events Risk Score (GRACE RS), derived from an international registry, are
two of the most renowned.7.9 However, their effectiveness has not been sufficiently verified in representative patient
populations, necessitating this research.
A total of 145 confirmed STEMI cases were investigated, with TIMI risk scores calculated and analysed in relation
to several relevant parameters. The age and gender distribution of the participants in this study was mainly similar to
that of past similar studies, allowing for fair comparisons. 10-12
Chest pain was the ubiquitous presentation amongst participants in the current study, which is similar to the 95%
positivity reported by Berg J et al and to the findings of Zucker D et al.13,14 The average time elapsed before the
patient could reach medical facility was 10.4+11.31 hours; much higher than that reported by Jacqueline L et al
(6.7+8.6 hours), but comparable to the mean 10.6 hours reported by Zornoff et al in their Canadian study in
1996.10,15 The reason of discordance here could be due to relatively lesser penetration of specialized health services
in our country, apparently similar to the Canadian health services in the 1990s.
According to the TIMI risk score, 54.5 percent of the 145 patients were in the low-risk group, 33.1 percent in the
moderate-risk group, and 12.4% in the high-risk group, with the high-risk group having the highest mortality (55.6
percent ).
Previous studies have found a similar distribution of TIMI risk scores among MI patients, as well as similar high
mortality rates, adding to the evidence that TIMI risk score is a predictor of mortality in the studied scenario.10-12,16
Hypertension and smoking were the most common risk factors in the present study and the subsequent mortality and
TIMI risk score grouping revealed significant associations for all the mentioned risk factors, much in line with the
available literature.14-16 A total of 44 (30.3%) participants belonged to Killips classification grade 2-4, and with the
relative risk being significant at more than 15, it was the single biggest determinant of in-hospital mortality in the
present study. Previous researchers seemed to have under-grouped the Killips classified cases.10,11 Nonetheless,
there is agreement over their important predictive role, with Jacqueline L et al, among others, reporting the mortality
among Killips class 2-4 to be as high as 54.8%.10,17 Systolic BP <100 mmHg was the other significant determinant
of death (RR-10.5). This is also much in-line with the available literature, reported more prominently in the elderly
population.10,11,18
Systolic BP <100 mmHg, HR >100/min, elapsed time >4 hours, weight <67kg, extensive ant. wall MI,
hospitalisation time <24hrs, elevated blood pressure was some of the variables which confirmed the discriminatory
role of TIMI risk score, as their frequency was observed to be more in high risk group as compared to moderate and
low risk groups. This important sits perfectly well with the findings of previous similar studies.10,12,15-17 The
discriminatory capacity of the TIMI risk score was further confirmed by the significant area under ROC curve
(0.86).
Conclusion:-
The study concludes that in STEMI cases, the greater the TIMI risk score upon admission, the worse the prognosis.
The TIMI risk score system appears to be a straightforward, valid, and useful bedside tool for quantitative risk
classification and short-term prognosis prediction in STEMI patients, and it is recommended for this purpose.
ISSN: 2320-5407 Int. J. Adv. Res. 9(12), 403-407
407
Funding:
No funding sources
Conflict of interest:
None declared
Ethical approval:
The study was approved by the Institutional Ethics Committee
References:-
1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235
causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study
2010. The Lancet. 2012 Dec 15;380(9859):2095-128.
2. Joshi P, Islam S, Pais P, Reddy S, Dorairaj P, Kazmi K, et al. Risk factors for early myocardial infarction in South
Asians compared with individuals in other countries. JAMA. 2007;297:286-94.
3. Xavier D, Pais P, Devereaux PJ, Xie C, Prabhakaran D, Reddy KS, et al. Treatment and outcomes of acute
coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet. 2008;371:1435-42.
4. Institute of Health Metrics and Evaluation. GBD Compare 2010, Available at: http://vizhub.healthdata.org/gbd-
compare/. Accessed on December 10, 2019.
5. Third International Study of Infarct Survival (ISIS-3) Collaborative Group. ISIS-3: A randomized comparison of
streptokinase vs. tissue plasminogen activators vs. Anistreplase and of Aspirin plus heparin vs. Aspirin alone among
41299 cases of suspected myocardial infarction. Lancet. 1993;329:753-70.
6. Lee KL. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Circulation.
1995;91:1659-68.
7. Garcia-Almagro FJ, Gimeno JR, Villegas M. Prognostic value of the Thrombolysis in Myocardial Infarction
(TIMI) risk score in an unselected population with chest pain. Construction of a new predictive model. Am J Emerg
Med. 2008;26:439-45.
8. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the
management of patients with ST-elevation myocardial infarction: executive summary: a report of the ACC/AHA
Task Force on practice guidelines (committee to revise the 1999 guidelines on the management of patients with
acute myocardial infarction). J Am Coll Cardiol. 2004;44:671-719.
9. Granger CB, Goldberg RJ, Dabbous O. Predictors of hospital mortality in the global registry of acute coronary
events. Arch Intern Med. 2003;163:2345-53.
10. Jacqueline L, Pareira N. TIMI risk score for acute myocardial infarction according to prognostic stratification.
Arq Bras Cardiol. 2009;93(2):100-6.
11. Hector Gonzales-Pacheo. The TIMI risk score for STEMI predicts in-hospital mortality and adverse events in
patients without cardiogenic shock undergoing primary angioplasty. Arch Cardiol Mex. 2012;82(1):7-13.
12. Morrow DA, Antman EM, Charlesworth A. TIMI risk score for ST elevation myocardial infarction: a
convenient, bedside, clinical score for risk assessment at presentation. Circulation. 2000;102:2013-7.
13. Berg J, Bjorg L, Dudas K. Symptoms of first myocardial infarction in women and men. Gender Med.
2009;6(3):454-62.
14. Zucker D, Griffith J, Beshansky J. Presentation of acute myocardial infarction in men and women. J Gen Intern
Med. 1997;12(2):79-87.
15. Zornoff L, Paiva SA, Assalin VM. Myocardial infarction patients in the 1990s: their risk factors, stratification
and survival in Canada: The Canadian Assessment of Myocardial Infarction (CAMI) Study. J am Coll Cardiol.
1996;27:1119-27.
16. Masood A, Quazi S. In-house outcome of acute myocardial infarction in correlation with ‘Thrombolysis in
Myocardial Infarction’ risk score. J Ayub Med Coll, Abottabad. 2009;21(4):23-8.
17. Lee K, Woolife L, Topol E. Predictors of 30-day mortality in the era of reperfusion for acute myocardial
infarction- Results from an international trial of 41021 patients. Circulation. 1995;91:1659-68.
18. Molander L, Lovheim H, Norman T. Lower systolic blood pressure is associated with greater mortality in people
aged 85 and older. Circulation. 2008;10:1853-9.
ResearchGate has not been able to resolve any citations for this publication.
Article
Full-text available
South Asians have high rates of acute myocardial infarction (AMI) at younger ages compared with individuals from other countries but the reasons for this are unclear. To evaluate the association of risk factors for AMI in native South Asians, especially at younger ages, compared with individuals from other countries. Standardized case-control study of 1732 cases with first AMI and 2204 controls matched by age and sex from 15 medical centers in 5 South Asian countries and 10,728 cases and 12,431 controls from other countries. Individuals were recruited to the study between February 1999 and March 2003. Association of risk factors for AMI. The mean (SD) age for first AMI was lower in South Asian countries (53.0 [11.4] years) than in other countries (58.8 [12.2] years; P<.001). Protective factors were lower in South Asian controls than in controls from other countries (moderate- or high-intensity exercise, 6.1% vs 21.6%; daily intake of fruits and vegetables, 26.5% vs 45.2%; alcohol consumption > or =once/wk, 10.7% vs 26.9%). However, some harmful factors were more common in native South Asians than in individuals from other countries (elevated apolipoprotein B(100) /apolipoprotein A-I ratio, 43.8% vs 31.8%; history of diabetes, 9.5% vs 7.2%). Similar relative associations were found in South Asians compared with individuals from other countries for the risk factors of current and former smoking, apolipoprotein B100/apolipoprotein A-I ratio for the top vs lowest tertile, waist-to-hip ratio for the top vs lowest tertile, history of hypertension, history of diabetes, psychosocial factors such as depression and stress at work or home, regular moderate- or high-intensity exercise, and daily intake of fruits and vegetables. Alcohol consumption was not found to be a risk factor for AMI in South Asians. The combined odds ratio for all 9 risk factors was similar in South Asians (123.3; 95% confidence interval [CI], 38.7-400.2] and in individuals from other countries (125.7; 95% CI, 88.5-178.4). The similarities in the odds ratios for the risk factors explained a high and similar degree of population attributable risk in both groups (85.8% [95% CI, 78.0%-93.7%] vs 88.2% [95% CI, 86.3%-89.9%], respectively). When stratified by age, South Asians had more risk factors at ages younger than 60 years. After adjusting for all 9 risk factors, the predictive probability of classifying an AMI case as being younger than 40 years was similar in individuals from South Asian countries and those from other countries. The earlier age of AMI in South Asians can be largely explained by higher risk factor levels at younger ages.
Article
Full-text available
Background: Reliable and timely information on the leading causes of death in populations, and how these are changing, is a crucial input into health policy debates. In the Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010), we aimed to estimate annual deaths for the world and 21 regions between 1980 and 2010 for 235 causes, with uncertainty intervals (UIs), separately by age and sex. Methods: We attempted to identify all available data on causes of death for 187 countries from 1980 to 2010 from vital registration, verbal autopsy, mortality surveillance, censuses, surveys, hospitals, police records, and mortuaries. We assessed data quality for completeness, diagnostic accuracy, missing data, stochastic variations, and probable causes of death. We applied six different modelling strategies to estimate cause-specific mortality trends depending on the strength of the data. For 133 causes and three special aggregates we used the Cause of Death Ensemble model (CODEm) approach, which uses four families of statistical models testing a large set of different models using different permutations of covariates. Model ensembles were developed from these component models. We assessed model performance with rigorous out-of-sample testing of prediction error and the validity of 95% UIs. For 13 causes with low observed numbers of deaths, we developed negative binomial models with plausible covariates. For 27 causes for which death is rare, we modelled the higher level cause in the cause hierarchy of the GBD 2010 and then allocated deaths across component causes proportionately, estimated from all available data in the database. For selected causes (African trypanosomiasis, congenital syphilis, whooping cough, measles, typhoid and parathyroid, leishmaniasis, acute hepatitis E, and HIV/AIDS), we used natural history models based on information on incidence, prevalence, and case-fatality. We separately estimated cause fractions by aetiology for diarrhoea, lower respiratory infections, and meningitis, as well as disaggregations by subcause for chronic kidney disease, maternal disorders, cirrhosis, and liver cancer. For deaths due to collective violence and natural disasters, we used mortality shock regressions. For every cause, we estimated 95% UIs that captured both parameter estimation uncertainty and uncertainty due to model specification where CODEm was used. We constrained cause-specific fractions within every age-sex group to sum to total mortality based on draws from the uncertainty distributions. Findings: In 2010, there were 52·8 million deaths globally. At the most aggregate level, communicable, maternal, neonatal, and nutritional causes were 24·9% of deaths worldwide in 2010, down from 15·9 million (34·1%) of 46·5 million in 1990. This decrease was largely due to decreases in mortality from diarrhoeal disease (from 2·5 to 1·4 million), lower respiratory infections (from 3·4 to 2·8 million), neonatal disorders (from 3·1 to 2·2 million), measles (from 0·63 to 0·13 million), and tetanus (from 0·27 to 0·06 million). Deaths from HIV/AIDS increased from 0·30 million in 1990 to 1·5 million in 2010, reaching a peak of 1·7 million in 2006. Malaria mortality also rose by an estimated 19·9% since 1990 to 1·17 million deaths in 2010. Tuberculosis killed 1·2 million people in 2010. Deaths from non-communicable diseases rose by just under 8 million between 1990 and 2010, accounting for two of every three deaths (34·5 million) worldwide by 2010. 8 million people died from cancer in 2010, 38% more than two decades ago; of these, 1·5 million (19%) were from trachea, bronchus, and lung cancer. Ischaemic heart disease and stroke collectively killed 12·9 million people in 2010, or one in four deaths worldwide, compared with one in five in 1990; 1·3 million deaths were due to diabetes, twice as many as in 1990. The fraction of global deaths due to injuries (5·1 million deaths) was marginally higher in 2010 (9·6%) compared with two decades earlier (8·8%). This was driven by a 46% rise in deaths worldwide due to road traffic accidents (1·3 million in 2010) and a rise in deaths from falls. Ischaemic heart disease, stroke, chronic obstructive pulmonary disease (COPD), lower respiratory infections, lung cancer, and HIV/AIDS were the leading causes of death in 2010. Ischaemic heart disease, lower respiratory infections, stroke, diarrhoeal disease, malaria, and HIV/AIDS were the leading causes of years of life lost due to premature mortality (YLLs) in 2010, similar to what was estimated for 1990, except for HIV/AIDS and preterm birth complications. YLLs from lower respiratory infections and diarrhoea decreased by 45-54% since 1990; ischaemic heart disease and stroke YLLs increased by 17-28%. Regional variations in leading causes of death were substantial. Communicable, maternal, neonatal, and nutritional causes still accounted for 76% of premature mortality in sub-Saharan Africa in 2010. Age standardised death rates from some key disorders rose (HIV/AIDS, Alzheimer's disease, diabetes mellitus, and chronic kidney disease in particular), but for most diseases, death rates fell in the past two decades; including major vascular diseases, COPD, most forms of cancer, liver cirrhosis, and maternal disorders. For other conditions, notably malaria, prostate cancer, and injuries, little change was noted. Conclusions: Population growth, increased average age of the world's population, and largely decreasing age-specific, sex-specific, and cause-specific death rates combine to drive a broad shift from communicable, maternal, neonatal, and nutritional causes towards non-communicable diseases. Nevertheless, communicable, maternal, neonatal, and nutritional causes remain the dominant causes of YLLs in sub-Saharan Africa. Overlaid on this general pattern of the epidemiological transition, marked regional variation exists in many causes, such as interpersonal violence, suicide, liver cancer, diabetes, cirrhosis, Chagas disease, African trypanosomiasis, melanoma, and others. Regional heterogeneity highlights the importance of sound epidemiological assessments of the causes of death on a regular basis. Funding: Bill & Melinda Gates Foundation.
Article
Full-text available
Introduction: Patients with ST elevation acute myocardial infarction (STEMI) comprise a heterogeneous population with respect to the risk for adverse events. Primary percutaneous coronary intervention (PCI) has shown to be better, mainly in high-risk patients. Objective: The purpose of this study was to determine if the Thrombolysis in Myocardial Infarction (TIMI) risk score for STEMI applied to patients undergo primary PCI identifies a group of patients at high risk for adverse events. Methods: We identified patients with STEMI without cardiogenic shock on admission, who were treated with primary PCI. The TIMI and CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) risk scores were calculated to determine their predictive value for in hospital mortality. Patients were divided into two groups according to their TIMI risk score, low risk being 0-4 points and high risk .5 points, and the frequency of adverse events was analyzed. Results: We analyzed 572 patients with STEMI. The c-statistics predictive value of the TIMI risk score for mortality was 0.80 (p=0.0001) and the CADILLAC risk score was 0.83, (p=0.0001). Thirty-two percent of patients classified as high risk (TIMI .5) had a higher incidence of adverse events than the low-risk group: mortality 14.8% vs. 2.1%, (p=0.0001); heart failure 15.3% vs. 4.1%, (p=0.0001); development of cardiogenic shock 10.9% vs. 1.5%, (p=0.0001); ventricular arrhythmias 14.8% vs. 5.9%, (p=0.001); and no-reflow phenomenon 22.4% vs. 13.6%, (p=0.01). Conclusions: The TIMI risk score for STEMI prior to primary PCI can predict in hospital mortality and identifies a group of high-risk patients who might develop adverse events.
Article
Full-text available
The TIMI (Thrombolysis in Myocardial Infarction) risk score is derived from clinical trial involving patients who are eligible for fibrinolysis. As the risk profiles of these cases differ from those found in non-selected populations, it is important to review the applicability of the score in usual clinical conditions. To evaluate the management and clinical evolution of hospital inpatients with acute myocardial infarction, according to risk stratification by the TIMI score. We evaluated, retrospectively, 103 cases of acute myocardial infarction with ST-segment elevation admitted to the Hospital Nossa Senhora da Conceição - Tubarão, in 2004 and 2005. The cases were analyzed in three risk groups according to the TIMI score. The hospital mortality after infarction was 17.5%. In the low-risk group there was no death. The mortality was 8.1% in the medium risk group and 55.6% in the high-risk group. The risk of death in cases of high risk was 14.1 times higher than in the cases of medium and low risk (95% CI = 4.4 to 44.1 and p <0.001). The chance of receiving fibrinolytic was 50% lower in the high-risk group in relation to the low risk group (95% CI = 0.27 to 0.85, p = 0.004). There was a progressive increase in mortality and incidence of in-hospital complications according to the stratification by the TIMI score. High risk patients received thrombolytic less frequently than the patients at low risk.
Article
To investigate the association between blood pressure and mortality in very old people. Population-based cohort study. County of Västerbotten, Sweden. Half of all subjects aged 85 and all of those aged 90 and 95 and older (N=348) in one urban and five rural municipalities in the north of Sweden. Among others, supine blood pressure, Mini-Mental State Examination, Barthel Index of activities of daily living, Mini Nutritional Assessment, and body mass index. Information on diagnoses, medications, and 4-year mortality was collected. Associations between blood pressure and mortality were investigated using Cox regression analyses, controlling for a number of diagnoses and health factors. Baseline systolic blood pressure (SBP), diastolic blood pressure, and pulse pressure were all inversely associated with mortality within 4 years according to univariate analysis. SBP was the strongest predictor. In Cox regression analyses, low SBP (<or=120 mmHg) correlated with greater 4-year all-cause mortality alone and when controlling for health status. This connection persisted after exclusion of deaths within the first year. There was a tendency toward a U-shaped mortality curve for the adjusted model, with SBP of 164.2 mmHg (95% confidence interval=154.1-183.8 mmHg) being associated with the lowest mortality. Lower SBP seems to be associated with greater mortality in people aged 85 and older, irrespective of health status. There are indications of a U-shaped correlation between SBP and mortality, and the optimal SBP for this age group could be above 140 mmHg.
Article
Despite remarkable advances in the treatment of acute myocardial infarction, substantial early patient mortality remains. Appropriate choices among alternative therapies and the use of clinical resources depend on an estimate of the patient's risk. Individual patients reflect a combination of clinical features that influence prognosis, and these factors must be appropriately weighted to produce an accurate assessment of risk. Prior studies to define prognosis either were performed before widespread use of thrombolysis or were limited in sample size or spectrum of data. Using the large population of the GUSTO-I trial, we performed a comprehensive analysis of relations between baseline clinical data and 30-day mortality and developed a multivariable statistical model for risk assessment in candidates for thrombolytic therapy. For the 41,021 patients enrolled in GUSTO-I, a randomized trial of four thrombolytic strategies, relations between clinical descriptors routinely collected at initial presentation, and death within 30 days (which occurred in 7% of the population) were examined with both univariable and multivariable analyses. Variables studied included demographics, history and risk factors, presenting characteristics, and treatment assignment. Risk modeling was performed with logistic multiple regression and validated with bootstrapping techniques. Multivariable analysis identified age as the most significant factor influencing 30-day mortality, with rates of 1.1% in the youngest decile (< 45 years) and 20.5% in patients > 75 (adjusted chi 2 = 717, P < .0001). Other factors most significantly associated with increased mortality were lower systolic blood pressure (chi 2 = 550, P < .0001), higher Killip class (chi 2 = 350, P < .0001), elevated heart rate (chi 2 = 275, P < .0001), and anterior infarction (chi 2 = 143, P < .0001). Together, these five characteristics contained 90% of the prognostic information in the baseline clinical data. Other significant though less important factors included previous myocardial infarction, height, time to treatment, diabetes, weight, smoking status, type of thrombolytic, previous bypass surgery, hypertension, and prior cerebrovascular disease. Combining prognostic variables through logistic regression, we produced a validated model that stratified patient risk and accurately estimated the likelihood of death. The clinical determinants of mortality in patients treated with thrombolytic therapy within 6 hours of symptom onset are multifactorial and the relations complex. Although a few variables contain most of the prognostic information, many others contribute additional independent prognostic information. Through consideration of multiple characteristics, including age, medical history, physiological significance of the infarction, and medical treatment, the prognosis of an individual patient can be accurately estimated.
Article
This study sought to evaluate the in-hospital and postdischarge mortality of patients with an acute myocardial infarction in the 1990s. The widespread implementation of therapeutic interventions that modify the natural history of coronary artery disease has led to changes in the profile and survival of patients with an acute myocardial infarction. Although data exist for selected subsets of patients with an acute myocardial infarction, at this time there is little recent prospective information on all patients presenting with an acute myocardial infarction, particularly for survival after hospital discharge. All patients < or = 75 years old presenting with an acute myocardial infarction between July 1, 1990 and June 30, 1992 at nine Canadian hospitals were prospectively evaluated and followed up for 1 year. From November 1991, patients of all ages were included. In two centers, recruitment continued until December 31, 1992. A total of 3,178 patients were recruited. The in-hospital mortality rate of patients < or = 75 years old was 8.4%, and that at 1 year after hospital discharge was 5.3%. For patients of all ages recruited after November 1, 1991, the in-hospital mortality rate was 9.9% and 7.1% for 1 year after hospital discharge. For patients < or = 75 years old, age carried an independent in-hospital but no post discharge risk. Female patients had a twofold greater risk of dying in hospital. After hospital discharge, only 1.7% of patients < or = 75 years old and 1.9% of patients of all ages died of a presumed arrhythmic death. Premature ventricular contractions had no independent prognostic value. The relatively low in-hospital (5.3%) and postdischarge (6.1%) reinfarction rate may have contributed to improved survival. A greater reinfarction rate in patients >75 years old (17.4% vs. 9.6%, p < 0.001) may have contributed to their poorer outcome. One-year mortality after acute myocardial infarction continues to decrease, and changes in the prognostic value of traditional methods of risk stratification have occurred.